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To The Editor: The excellent article by Dr Elmehdawi RR 
entitled “Hypolipidemia: A word of caution” has once again 
shown the multifaceted properties of cholesterol which is 
the most highly decorated molecule in biology [1]. Thirteen 
nobel prizes have been awarded to scientists who devoted 
major parts of their careers to cholesterol [2]. 
 
The word cholesterol is derived from the Greek words, 
chole= bile; steros= solid; ol= alcohol. Ever since it was 
first isolated from gallstones in 1784, cholesterol has 
exerted a hypnotic fascination for scientists from most 
diverse domains of science and medicine. Organic chemists 
have been fascinated with cholesterol because of its 
complex four ring structure with its steroid nucleus. 
Biochemists have also been interested because cholesterol 
is synthesized from a simple two-carbon substrate, acetate, 
through the action of at least 30 enzymes. Besides, 
cholesterol drew the attention of physiologists and cell 
biologists because of its essential function in animal cell 
membranes, where it modulates fluidity and maintains a 
barrier between cell and environment and being the raw 
material for the manufacture of steroid hormones and bile 
acids. Physicians started studying cholesterol after it has 
become evident that elevated levels of blood cholesterol 
accelerate the formation of atherosclerotic plaques leading 
to heart attack and stroke. Over the course of nearly a 
century of investigation, researchers have developed four 
lines of evidence: experimental, genetic, epidemiologic, and 
therapeutic - that irrefutably established the causal 
connection between cholesterol carrying low density 
lipoprotein (LDL) and atherosclerosis [3]. Few other major 
diseases have been subject to such intensive and ultimately 
fruitful research. Building on that knowledge scientists have 
been successful in developing an effective course of 
therapy – the statin drugs which are inhibitors of 3-
hydroxy-3-methyl glutaryl coenzyme A reductase (HMG CoA 
reductase), the rate limiting enzyme in cholesterol 
biosynthesis. 
 
High –density lipoprotein (HDL) cholesterol represent a 
strong inverse predicator of cardiovascular events. Recent 
studies have illustrated the clinical significance of high-
density lipoprotein cholesterol in patients with low levels of 
low-density lipoprotein cholesterol [4, 5]. HDL cholesterol 
levels were predictive of major cardiovascular events in 
patients treated with statins. This relationship was also 
observed among patients with LDL cholesterol below 70 mg 
per deciliter. 
 
As suggested by Dr Elmehdawi, caution needs to be 
asserted as we focus on aggressive management of 
hyperlipidemia due to the possible complications of drug 
induced hypolipidemia including intracerebral hemorrhage 
and sepsis [1]. There has been controversy in the literature 
concerning the contribution of hypercholesterolemia to 
subsequent development of dementia [6]. Longitudinal 
studies have established that midlife elevated serum 
cholesterol level is associated with an increased risk of 
subsequent Alzheimer’s disease [7]. 
 
However, two large randomized controlled trials failed 
to show that statins (pravastatin and simvastatin) 
reduced dementia [8, 9]. Hypocholesterolemia is also a 
predisposing factor for infection in certain conditions as 
well as a prognostic indicator during sepsis [1]. But a 
recent systematic review, which analyzed studies of the 
literature comparing  the outcome between statin and 
non- statin users among patients suffering from sepsis or 
other infections, reported a major consensus that statins 
may have a positive role in treatment of patients with 
sepsis and infection [10]. Heart failure (HF) is a common 
and a serious condition that is usually due to coronary 
artery disease (CAD). Hypercholesterolemia is a major 
risk factor for CAD but, paradoxically, patients with 
advanced HF often have low cholesterol, which is 
associated with poor prognosis [11]. Hence, even after 
200 years of first being isolated, and nearly 100 years of 
fruitful research, this Janusfaced molecule continues to 
evoke controversy, and the debate on the role of 
cholesterol in biomedicine and the future direction of 
cholesterol-lowering therapy continues. 
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